Verona Pharma PLC
NASDAQ:VRNA

Watchlist Manager
Verona Pharma PLC Logo
Verona Pharma PLC
NASDAQ:VRNA
Watchlist
Price: 45.04 USD -0.53% Market Closed
Market Cap: 3.7B USD
Have any thoughts about
Verona Pharma PLC?
Write Note

Verona Pharma PLC
Research & Development

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Verona Pharma PLC
Research & Development Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Research & Development CAGR 3Y CAGR 5Y CAGR 10Y
Verona Pharma PLC
NASDAQ:VRNA
Research & Development
-$40.8m
CAGR 3-Years
15%
CAGR 5-Years
7%
CAGR 10-Years
N/A
GlaxoSmithKline PLC
LSE:GSK
Research & Development
-ÂŁ6B
CAGR 3-Years
-10%
CAGR 5-Years
-8%
CAGR 10-Years
-6%
AstraZeneca PLC
LSE:AZN
Research & Development
-$11B
CAGR 3-Years
-31%
CAGR 5-Years
-14%
CAGR 10-Years
-9%
Indivior PLC
LSE:INDV
Research & Development
-$102m
CAGR 3-Years
-32%
CAGR 5-Years
-12%
CAGR 10-Years
-1%
Hikma Pharmaceuticals PLC
LSE:HIK
Research & Development
-$146m
CAGR 3-Years
-3%
CAGR 5-Years
-3%
CAGR 10-Years
-14%
Dechra Pharmaceuticals PLC
LSE:DPH
Research & Development
-ÂŁ57.5m
CAGR 3-Years
-27%
CAGR 5-Years
-26%
CAGR 10-Years
-22%
No Stocks Found

Verona Pharma PLC
Glance View

Market Cap
3.7B USD
Industry
Pharmaceuticals

Verona Pharma PLC, an ambitious player in the biopharmaceutical arena, is woven into the intricate tapestry of the healthcare industry, focusing its energies on respiratory ailments. Born within the thriving biopharma sector in London, this company has targeted chronic obstructive pulmonary disease (COPD) with its novel therapies, driven by the urgent need to alleviate this global burden. The company's flagship product, ensifentrine, serves as a dual inhibitor of the enzymes phosphodiesterase 3 and 4, aiming to enhance lung function and ease the constriction challenges faced by patients. Through strategic clinical trials and robust scientific inquiry, Verona Pharma seeks not only to innovate in treatment but also to deliver tangible hope for those grappling with chronic respiratory conditions. Verona Pharma's business model is anchored in advancing its drug development pipeline, propelled by a blend of scientific rigor and strategic partnerships. It capitalizes on patent protection and licensing agreements to secure its financial footing, investing heavily in research to drive value creation. The company earns its revenue predominantly from collaborative agreements with larger pharmaceutical entities, milestone payments, and potential royalties upon successful commercialization of its therapies. Through aligning with other industry giants, Verona Pharma not only financially fortifies its pursuits but also accelerates the dissemination of its therapeutic innovations, ensuring that their beneficial impacts reach as many patients as possible. This harmonized approach with partners places Verona Pharma on a trajectory not just of financial growth but also of achieving its underlying mission – transforming the landscape of respiratory disease management.

VRNA Intrinsic Value
14.59 USD
Overvaluation 68%
Intrinsic Value
Price

See Also

What is Verona Pharma PLC's Research & Development?
Research & Development
-40.8m USD

Based on the financial report for Sep 30, 2024, Verona Pharma PLC's Research & Development amounts to -40.8m USD.

What is Verona Pharma PLC's Research & Development growth rate?
Research & Development CAGR 5Y
7%

Over the last year, the Research & Development growth was -74%. The average annual Research & Development growth rates for Verona Pharma PLC have been 15% over the past three years , 7% over the past five years .

Back to Top